New combination treatments in the management of diabetes: focus on sitagliptin – metformin
Jennifer Green, Mark FeinglosDuke University Medical Center, Department of Medicine, Division of Endocrinology, Durham, North Carolina, USAAbstract: Type 2 diabetes mellitus is an increasingly prevalent condition worldwide. The complications of this disease are known to significantly increase the mo...
Main Authors: | Jennifer Green, Mark Feinglos |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2008-08-01
|
Series: | Vascular Health and Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/new-combination-treatments-in-the-management-of-diabetes-focus-on-sita-peer-reviewed-article-VHRM |
Similar Items
-
Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01) -
Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
by: Alexander Sergeevich Ametov, et al.
Published: (2010-09-01) -
Combination treatment for type 2 diabetes mellitus (T2DM) : dipeptidyl peptidase-4 inhibitors (DPP-4) and metformin
by: Erna Kristin
Published: (2017-10-01) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01) -
Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)